腫瘤臨床試驗市場規模、佔有率和成長分析：按階段、治療方法、癌症類型、適應症、最終用戶和地區分類－2026-2033年產業預測

2024 年全球腫瘤臨床試驗市場價值為 147 億美元，預計到 2033 年將從 2025 年的 154.1 億美元成長到 224.2 億美元，預測期（2026-2033 年）複合年成長率為 4.8%。

當前市場趨勢表明，分子生物學和精準醫學的進步正顯著推動腫瘤臨床試驗領域的發展。先進的基因組分析和生物標記發現技術正在加速標靶治療的研究，並帶來更高的緩解率。該市場涵蓋了多種腫瘤適應症的治療和診斷藥物的臨床開發，直接影響患者的生存率和醫療成本。從廣泛的化療試驗轉向適應性強、以生物標記主導導向的研究，凸顯了創新試驗設計的重要性。監管的柔軟性支持了諸如傘式試驗和籃式試驗等方法，從而簡化了針對生物標記定義人群的試驗流程。人工智慧在患者招募流程中的應用，利用電子健康記錄最佳化了候選患者的識別，提高了效率和覆蓋範圍。總而言之，對技術和創新試驗設計的投資正在為市場擴張和改善患者預後創造新的機會。

全球腫瘤臨床試驗市場的促進因素

全球腫瘤臨床試驗市場正受到製藥公司和創業投資資金投入增加的顯著推動。這些資金不僅支持腫瘤臨床試驗計畫的拓展，也加速了標靶治療和個人化療法的研發。資源的增加使申辦方能夠進行更複雜的研究，專注於基於生物標記的患者篩選，並繼續進行長期、多中心試驗，以探索創新的作用機制。此外，資金的增加也促進了基礎設施的改進，例如數位化臨床試驗平台和專業檢測能力的提升，從而提高了臨床試驗的效率並擴大了患者的參與範圍。因此，投資的增加拓寬了進入臨床試驗階段的治療方案範圍，最終推動了市場成長。

全球腫瘤臨床試驗市場的限制因素

監管要求的複雜性和不斷變化給癌症臨床試驗市場帶來了巨大挑戰，給申辦方在文件編制、監督和合規方面造成了沉重負擔。試驗設計和病患安全監測標準的區域差異可能導致試驗啟動延遲，並使全球計畫的協調更加複雜。滿足嚴格的安全性和有效性預期通常需要額外的支持性研究以及與監管機構的持續合作，這會消耗寶貴的組織資源，並阻礙其專注於拓展治療方案組合。因此，複雜的監管環境可能會阻礙新癌症治療方法在臨床開發平臺中的進展速度。

全球腫瘤臨床試驗市場趨勢

全球腫瘤臨床試驗市場正經歷著數位化和遠端試驗模式的顯著轉變，這主要得益於分散式調查方法的日益普及。這些創新方法利用遠端醫療行動醫療工具和遠端監測，提升了受試者的參與度和便利性，並透過靈活的日程安排和居家數據收集，最終提高了受試者的保留率。穿戴式感測器和電子知情同意平台的整合，促進了患者的持續參與和即時數據收集，使申辦方能夠有效地觸及不同的目標族群。這種轉變不僅加快了研發週期，而且透過標準化的數位化工作流程和集中監管來維護資料完整性，從而支持癌症研究的適應性營運策略和擴充性。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球腫瘤臨床試驗市場規模：依階段分類

• 第一階段
• 第二階段
• 第三階段
• 第四階段

全球腫瘤臨床試驗市場規模：依治療類型分類

• 化療
• 免疫療法
• 標靶治療
• 荷爾蒙療法
• 細胞和基因治療
• 放射性藥物療法
• 其他

全球腫瘤臨床試驗市場規模：依癌症類型分類

• 固體癌
• 骨髓惡性腫瘤

全球腫瘤臨床試驗市場規模：依適應症分類

• 乳癌
• 肺癌
• 結腸癌
• 攝護腺癌
• 卵巢癌
• 肝癌
• 胃癌
• 胰臟癌
• 白血病
• 淋巴瘤
• 多發性骨髓瘤
• 其他

全球腫瘤臨床試驗市場規模：依最終用戶分類

• 醫院和癌症中心
• 受託研究機構（CRO）
• 大學醫院
• 其他

全球腫瘤臨床試驗市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• IQVIA
• Parexel International
• ICON plc
• PPD
• Syneos Health
• Labcorp Drug Development
• Worldwide Clinical Trials
• Novotech
• Precision for Medicine
• Catalyst Oncology
• Medpace
• Ergomed
• Clario
• Quanticate
• Medelis
• Sofpromed
• Criterium
• Thermo Fisher Scientific
• WuXi AppTec
• Charles River Laboratories

結論與建議

Global Oncology Clinical Trials Market size was valued at USD 14.7 Billion in 2024 and is poised to grow from USD 15.41 Billion in 2025 to USD 22.42 Billion by 2033, growing at a CAGR of 4.8% during the forecast period (2026-2033).

Current market insights indicate that advancements in molecular biology and precision medicine are significantly driving the oncology clinical trials sector. Enhanced genomic profiling and biomarker discovery facilitate targeted studies with elevated response rates. This market includes clinical development for therapeutics and diagnostics across various oncology indications, directly influencing patient survival and healthcare costs. The transition from broad chemotherapy trials to adaptive, biomarker-driven studies underlines the importance of innovative trial designs. Regulatory flexibility supports approaches like umbrella and basket trials, streamlining testing across biomarker-defined populations. The integration of AI into patient recruitment processes optimizes candidate identification using electronic health records, enhancing efficiency and outreach. Overall, investments in technology and innovative trial designs are creating new opportunities for market expansion and improved patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oncology Clinical Trials market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oncology Clinical Trials Market Segments Analysis

Global oncology clinical trials market is segmented by phase, therapy type, cancer type, indication, end user and region. Based on phase, the market is segmented into Phase I, Phase II, Phase III and Phase IV. Based on therapy type, the market is segmented into Chemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy, Cell & Gene Therapy, Radiopharmaceutical Therapy and Others. Based on cancer type, the market is segmented into Solid Tumors and Hematologic Malignancies. Based on indication, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Liver Cancer, Gastric Cancer, Pancreatic Cancer, Leukemia, Lymphoma, Multiple Myeloma and Others. Based on end user, the market is segmented into Hospitals & Cancer Centers, Contract Research Organizations (CROs), Academic Medical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Oncology Clinical Trials Market

The Global Oncology Clinical Trials market is significantly driven by heightened financial backing from pharmaceutical companies and venture capital. This influx of funding not only supports the expansion of oncology clinical trial pipelines but also facilitates the advancement of targeted and personalized therapies. With increased resources, sponsors can embark on more intricate studies, emphasizing biomarker-driven patient selection and sustaining longer multicenter trials that investigate innovative mechanisms of action. Furthermore, this enhanced funding bolsters infrastructure improvements, such as digital trial platforms and specialized laboratory capabilities, which elevate trial efficiency and broaden patient access. As a result, greater investment fosters a wider array of investigational treatments moving through clinical phases, thereby propelling market growth.

Restraints in the Global Oncology Clinical Trials Market

The complexity and evolving nature of regulatory requirements present significant challenges for the oncology clinical trials market, introducing substantial demands for documentation, oversight, and compliance from sponsors. Variations in regional standards for trial design and patient safety monitoring lead to potential delays in study initiation and complicate the coordination of global programs. To meet rigorous safety and efficacy expectations, additional supporting studies and ongoing engagement with regulatory bodies are often required, consuming valuable organizational resources and detracting focus from expanding therapy portfolios. As a result, the intricate regulatory landscape can hinder the speed at which new oncology treatments advance through the clinical development pipeline.

Market Trends of the Global Oncology Clinical Trials Market

The Global Oncology Clinical Trials market is witnessing a significant trend towards digital and remote trial models, driven by the increasing adoption of decentralized methodologies. These innovative approaches utilize telemedicine, mobile health tools, and remote monitoring to enhance participant access and convenience, ultimately improving retention through flexible scheduling and at-home data collection. The integration of wearable sensors and electronic consent platforms facilitates continuous patient engagement and real-time data capture, allowing sponsors to reach diverse populations effectively. This shift not only accelerates development cycles but also maintains data integrity through standardized digital workflows and centralized oversight, supporting adaptive operational strategies and scalability within oncology research.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Oncology Clinical Trials Market Size by Phase & CAGR (2026-2033)

• Market Overview
• Phase I
• Phase II
• Phase III
• Phase IV

Global Oncology Clinical Trials Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Hormonal Therapy
• Cell & Gene Therapy
• Radiopharmaceutical Therapy
• Others

Global Oncology Clinical Trials Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Solid Tumors
• Hematologic Malignancies

Global Oncology Clinical Trials Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Ovarian Cancer
• Liver Cancer
• Gastric Cancer
• Pancreatic Cancer
• Leukemia
• Lymphoma
• Multiple Myeloma
• Others

Global Oncology Clinical Trials Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Cancer Centers
• Contract Research Organizations (CROs)
• Academic Medical Centers
• Others

Global Oncology Clinical Trials Market Size & CAGR (2026-2033)

• North America (Phase, Therapy Type, Cancer Type, Indication, End User)
  • US
  • Canada
• Europe (Phase, Therapy Type, Cancer Type, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Phase, Therapy Type, Cancer Type, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Phase, Therapy Type, Cancer Type, Indication, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Phase, Therapy Type, Cancer Type, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• IQVIA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PPD
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp Drug Development
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Worldwide Clinical Trials
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision for Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalyst Oncology
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medpace
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ergomed
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clario
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quanticate
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medelis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sofpromed
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Criterium
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations